Overview
Human growth hormone (HGH / somatropin) is investigated for its role in pituitary GH pathway activation and downstream IGF-1 signalling. The 36iu vial supplies a single lyophilised dose, suited to smaller or single-arm research programmes.
Nova Biolabs supplies HGH 36iu in lyophilised form from UK domestic stock.
Key Research Areas
Pituitary GH Pathway Research
HGH is studied for its direct activation of pituitary growth hormone receptors and downstream signalling cascades.
IGF-1 Signalling Studies
GH pathway activation drives hepatic IGF-1 production, a key readout in metabolic and endocrine research models.
Single-Vial Research Flexibility
A standalone 36iu vial suits smaller research programmes or preliminary studies before committing to a larger kit.
Comparative Dose-Response Research
Used alongside the 100iu kit in dose-response study designs comparing single vs. extended GH exposure protocols.
Product Specifications
| Format | Lyophilised powder |
| Quantity | 36iu per vial |
| Grade | Research Grade |
| Storage | Refrigerate at 2–8°C. Stable lyophilised. |
| Origin | UK domestic stock |
| Research use | In vitro / laboratory use only |
Frequently Asked Questions
Commonly Stacked With
Compounds researchers often study alongside this one, and why.
Secretagogue research (CJC-1295/Ipamorelin) is often studied alongside direct GH administration to compare endogenous-release vs. exogenous-replacement models.
A useful comparison pair for research distinguishing "encouraging the body’s own GH release" (Tesamorelin) from direct exogenous GH administration.
Both are foundational cellular-protection compounds — NAD+’s energy-pathway research is often studied alongside glutathione’s antioxidant research for broader cellular-health coverage.